NO20024478L - Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte östrogener og medroksyprogesteronacetat - Google Patents

Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte östrogener og medroksyprogesteronacetat

Info

Publication number
NO20024478L
NO20024478L NO20024478A NO20024478A NO20024478L NO 20024478 L NO20024478 L NO 20024478L NO 20024478 A NO20024478 A NO 20024478A NO 20024478 A NO20024478 A NO 20024478A NO 20024478 L NO20024478 L NO 20024478L
Authority
NO
Norway
Prior art keywords
combination
replacement therapy
hormone replacement
medroxyprogesterone acetate
conjugated estrogens
Prior art date
Application number
NO20024478A
Other languages
English (en)
Other versions
NO20024478D0 (no
NO326886B1 (no
Inventor
James Harrison Pickar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26886279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024478(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20024478D0 publication Critical patent/NO20024478D0/no
Publication of NO20024478L publication Critical patent/NO20024478L/no
Publication of NO326886B1 publication Critical patent/NO326886B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
NO20024478A 2000-03-20 2002-09-19 Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte ostrogener og medroksyprogesteronacetat NO326886B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19063000P 2000-03-20 2000-03-20
US26860701P 2001-02-14 2001-02-14
PCT/US2001/040302 WO2001070208A2 (en) 2000-03-20 2001-03-16 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate

Publications (3)

Publication Number Publication Date
NO20024478D0 NO20024478D0 (no) 2002-09-19
NO20024478L true NO20024478L (no) 2002-09-19
NO326886B1 NO326886B1 (no) 2009-03-16

Family

ID=26886279

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024478A NO326886B1 (no) 2000-03-20 2002-09-19 Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte ostrogener og medroksyprogesteronacetat

Country Status (30)

Country Link
US (2) US20010034340A1 (no)
EP (1) EP1265616B1 (no)
JP (1) JP2003527416A (no)
KR (1) KR100805648B1 (no)
CN (1) CN1239160C (no)
AR (1) AR031563A1 (no)
AT (1) ATE326227T1 (no)
AU (2) AU5003401A (no)
BG (1) BG66075B1 (no)
BR (1) BR0109334A (no)
CA (1) CA2402983A1 (no)
CY (1) CY1105632T1 (no)
CZ (1) CZ20023162A3 (no)
DE (1) DE60119703T2 (no)
DK (1) DK1265616T3 (no)
EA (1) EA005592B1 (no)
EE (1) EE05129B1 (no)
ES (1) ES2261393T3 (no)
HK (1) HK1049449B (no)
HR (1) HRP20020837B1 (no)
HU (1) HUP0302093A3 (no)
IL (1) IL151512A0 (no)
MX (1) MXPA02009116A (no)
NO (1) NO326886B1 (no)
NZ (1) NZ521171A (no)
PL (1) PL201762B1 (no)
PT (1) PT1265616E (no)
SK (1) SK286169B6 (no)
TW (1) TWI271194B (no)
WO (1) WO2001070208A2 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
EA200301022A1 (ru) * 2001-03-16 2004-02-26 Уайт Гормональная заместительная терапия
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
AU2003210759B2 (en) * 2002-04-03 2007-01-25 Barr Laboratories, Inc. Step-down estrogen therapy
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
CN101406464A (zh) * 2002-06-06 2009-04-15 霍尔莫斯医疗有限公司 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法
EP1515725A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
CA2489813A1 (en) * 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
US8349819B2 (en) 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP2289486A1 (en) 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
BRPI0709924A2 (pt) * 2006-04-05 2011-07-26 Wyeth Corp mÉtodo para prevenir ou tratar uma condiÇço decorrente de deficiÊncia de estrogÊnio local
RU2009117201A (ru) * 2006-11-29 2011-01-10 Вайет (Us) Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
ES2389961T3 (es) * 2007-02-14 2012-11-05 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US9734496B2 (en) 2009-05-29 2017-08-15 Paypal, Inc. Trusted remote attestation agent (TRAA)
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11224603B2 (en) * 2013-12-13 2022-01-18 Requis Pharmaceuticals, Inc. Antihistamines in combination with a range of substances for improved health
US10369158B2 (en) 2014-04-28 2019-08-06 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10821117B2 (en) 2014-09-02 2020-11-03 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
US10406169B2 (en) 2015-03-30 2019-09-10 The Regents Of The University Of California Methods of monitoring estriol therapy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US20210386757A1 (en) * 2018-10-17 2021-12-16 Sarah S. Stadler Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
BR0109334A (pt) 2002-12-24
CA2402983A1 (en) 2001-09-27
CN1239160C (zh) 2006-02-01
IL151512A0 (en) 2003-04-10
CY1105632T1 (el) 2010-12-22
EP1265616B1 (en) 2006-05-17
MXPA02009116A (es) 2003-03-12
CN1418102A (zh) 2003-05-14
BG66075B1 (en) 2011-02-28
EE05129B1 (et) 2009-02-16
WO2001070208A2 (en) 2001-09-27
US20090005351A1 (en) 2009-01-01
WO2001070208A3 (en) 2002-04-25
HUP0302093A2 (hu) 2003-10-28
HK1049449A1 (en) 2003-05-16
EE200200535A (et) 2004-04-15
CZ20023162A3 (cs) 2003-03-12
EA005592B1 (ru) 2005-04-28
AR031563A1 (es) 2003-09-24
PT1265616E (pt) 2006-08-31
NO20024478D0 (no) 2002-09-19
BG107095A (bg) 2003-05-30
US20010034340A1 (en) 2001-10-25
NO326886B1 (no) 2009-03-16
PL363157A1 (en) 2004-11-15
DE60119703D1 (de) 2006-06-22
HRP20020837A2 (en) 2004-02-29
HRP20020837B1 (en) 2007-08-31
EP1265616A2 (en) 2002-12-18
SK13482002A3 (sk) 2003-02-04
SK286169B6 (sk) 2008-04-07
NZ521171A (en) 2004-09-24
KR20020084230A (ko) 2002-11-04
HUP0302093A3 (en) 2010-03-29
ATE326227T1 (de) 2006-06-15
TWI271194B (en) 2007-01-21
HK1049449B (zh) 2006-07-28
PL201762B1 (pl) 2009-05-29
KR100805648B1 (ko) 2008-02-26
AU5003401A (en) 2001-10-03
AU2001250034B2 (en) 2005-03-24
DE60119703T2 (de) 2006-10-19
JP2003527416A (ja) 2003-09-16
ES2261393T3 (es) 2006-11-16
DK1265616T3 (da) 2006-06-12
EA200201000A1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
NO20024478D0 (no) Hormonerstatningsterapi ved anvendelse av kombinasjon av konjugerte östrogener og medroksyprogesteronacetat
AU3947902A (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AU6118001A (en) Combination therapeutic compositions and methods of use
NO20030030D0 (no) Farmasöytiske blandinger av östrogene midler
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF
HUP0204291A3 (en) Use of composition containing estrogen and drospirenone for hormone replacement therapy
AU2001273125A1 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
HU229606B1 (en) Novel combination of loteprednol and antihistamines
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001271785A1 (en) Combinations of statins, estrogenic agents and optionally estrogens
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2002217841A1 (en) Neuroactive steroid derivatives and methods of use
NO20030899D0 (no) Anvendelse av salmeterol og fluticasonpropionat kombinasjon
IL151523A0 (en) Use of avocado-soybean unsaponifiable preparations
NO20006381D0 (no) Terapeutiske kombinasjoner av (selektive) östrogenreseptormodulatorer (SERM) og veksthormonsekresjonsmidler
EP1330271A4 (en) USE OF TRANSCRIPTION FACTORS FOR THE TREATMENT OF INFLAMMATION AND OTHER DISEASES
AU2001283486A1 (en) Methods of modulating wound healing and angiogenesis
SI1265616T1 (sl) Hormonsko nadomestno zdravljenje z uporabo kombinacije konjugiranih estrogenov in medroksiprogesteron-acetata
AU4825200A (en) Oral steroidal hormone compositions and methods of use
PT1305314E (pt) Agente terapeutico cristalino
AU2092200A (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU2001296872A1 (en) Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
AU2001261180A1 (en) Combination therapeutic compositions and methods of use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees